For research use only. Not for therapeutic Use.
AZD8309 is an orally active antagonist of CXCR2. AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases[1].
AZD8309 (50 mg/kg; p.o.; twice daily) reduces neutrophil migration and pancreatic protease activation in experimental pancreatitis in mice[1].
| Catalog Number | I022887 |
| CAS Number | 333742-48-6 |
| Synonyms | 5-[(2,3-difluorophenyl)methylsulfanyl]-7-[[(2R)-1-hydroxypropan-2-yl]amino]-3H-[1,3]thiazolo[4,5-d]pyrimidin-2-one |
| Molecular Formula | C15H14F2N4O2S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H14F2N4O2S2/c1-7(5-22)18-12-11-13(21-15(23)25-11)20-14(19-12)24-6-8-3-2-4-9(16)10(8)17/h2-4,7,22H,5-6H2,1H3,(H2,18,19,20,21,23)/t7-/m1/s1 |
| InChIKey | SRHSMXLXWORYJK-SSDOTTSWSA-N |
| SMILES | CC(CO)NC1=NC(=NC2=C1SC(=O)N2)SCC3=C(C(=CC=C3)F)F |
| Reference | [1]. Malla SR, et al. Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis. Pancreatology. 2016 Sep-Oct;16(5):761-9. [2]. Walters I, Austin C, Austin R, et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett. 2008;18(2):798-803. |
